Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Curcumin × Genitourinary × Clear all

Phase

Status

Recruiting 4 Completed 3 Withdrawn 1 Unknown 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2 Other 1 Genitourinary 1 Breast 1

Conditions

Prostate Cancer Metastatic Castration Resistant 1

Interventions

Docetaxel 58 pembrolizumab 35 Prednisone 33 Nivolumab 33 enzalutamide 29 Gemcitabine 29 Sunitinib 27 Cyclophosphamide 26 Leuprolide 22 Everolimus 21 Sorafenib 20 Magnetic Resonance Spectroscopy 20 Radiotherapy 19 bicalutamide 17 Cisplatin 17 Abiraterone Acetate 17 avelumab 15 Interleukin-2 15 Radiosurgery 14 Goserelin 14 Carboplatin 14 fludarabine 13 atezolizumab 13 Radiotherapy, Intensity-Modulated 13 Bevacizumab 13 abiraterone 12 Doxorubicin 12 durvalumab 11 cabazitaxel 11 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02095717 2018-07-24

CURTAXEL

Centre Jean Perrin

Phase 2 Terminated

Prostate Cancer Metastatic Castration Resistant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡